Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Entrada Therapeutics (TRDA) EPS (Basic) (2022 - 2025)

Historic EPS (Basic) for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to -$1.06.

  • Entrada Therapeutics' EPS (Basic) fell 20285.71% to -$1.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.55, marking a year-over-year decrease of 25269.46%. This contributed to the annual value of $1.76 for FY2024, which is 97920.66% up from last year.
  • Entrada Therapeutics' EPS (Basic) amounted to -$1.06 in Q3 2025, which was down 20285.71% from -$1.04 recorded in Q2 2025.
  • Entrada Therapeutics' EPS (Basic)'s 5-year high stood at $1.61 during Q2 2024, with a 5-year trough of -$1.06 in Q3 2025.
  • In the last 4 years, Entrada Therapeutics' EPS (Basic) had a median value of -$0.42 in 2025 and averaged -$0.25.
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 43333.33% in 2024, then tumbled by 20285.71% in 2025.
  • Quarter analysis of 4 years shows Entrada Therapeutics' EPS (Basic) stood at -$0.78 in 2022, then surged by 62.82% to -$0.29 in 2023, then surged by 110.21% to $0.03 in 2024, then crashed by 3678.71% to -$1.06 in 2025.
  • Its EPS (Basic) was -$1.06 in Q3 2025, compared to -$1.04 in Q2 2025 and -$0.42 in Q1 2025.